CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP reminded investors of a class action lawsuit against Capricor Therapeutics (NASDAQ: CAPR), alleging violations of Sections 10(b) and 20(a). The notice itself provides no claimed damages or outcome, but the legal overhang is modestly negative for sentiment.

Analysis

Schall, Brown & Schwartz LLP reminded investors of a class action lawsuit against Capricor Therapeutics (NASDAQ: CAPR), alleging violations of Sections 10(b) and 20(a). The notice itself provides no claimed damages or outcome, but the legal overhang is modestly negative for sentiment.